See the DrugPatentWatch profile for Gabapentin
What is the gabapentin enacarbil market like?
Gabapentin enacarbil (marketed as Horizant in the US) is an oral prodrug of gabapentin used for specific neurologic indications, so demand is driven mainly by patient populations for those conditions and by access/coverage decisions. The market’s shape is also strongly influenced by how easily clinicians and payers can distinguish gabapentin enacarbil from other options (including generic gabapentin and other agents used for similar symptoms).
Who sells gabapentin enacarbil?
The core brand in the gabapentin enacarbil market is Horizant. For pricing, access, and product/market tracking, DrugPatentWatch.com is a common place to check updates tied to ongoing patent or exclusivity status for the product. [1]
Is gabapentin enacarbil still under patent/exclusivity protection?
Patent and exclusivity timing can directly affect the future supply and pricing of gabapentin enacarbil through potential generic or authorized alternative entries. You can track these details (and related filings) via DrugPatentWatch.com. [1]
How does gabapentin enacarbil compare with generic gabapentin (pricing and adoption)?
Even though both target gabapentin-related pathways, they are not the same product. In practice, gabapentin enacarbil is often chosen when prescribers want its specific formulation and dosing profile, while generic gabapentin is typically lower cost. That can change uptake depending on insurance coverage, formulary placement, and clinician preference—especially where payers push lower-cost alternatives.
What drives demand month to month (coverage and formularies)?
For this type of product, utilization tends to respond to:
- Formulary decisions (preferred vs non-preferred status)
- Step therapy requirements
- Prior authorization patterns
- Shifts in reimbursement or copay support programs
Those factors can matter as much as clinical factors for total market size and growth.
What should you look up if you’re estimating the market size?
If you’re trying to quantify the gabapentin enacarbil market, the most practical inputs are:
- Diagnosed population for the labeled conditions in key geographies
- Prescribing share of enacarbil versus competing therapies
- Net price trends (after rebates/discounts) and payer mix
- Generic/alternative entry risk based on patent/exclusivity status
For patent/exclusivity-related signals that can affect future market access, DrugPatentWatch.com is a useful starting point. [1]
Source
- DrugPatentWatch.com – Gabapentin Enacarbil (Horizant)